|
Glioblastoma Multiforme
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Finally, we found that EGFR gene amplifications were associated with distinct tumor infiltration patterns, thus representing a putative novel functional association between EGFR gene amplification and ARF1 gene promoter methylation in GB.
|
28631186 |
2017 |
|
Hepatitis C
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recent reports indicate that the replication of hepatitis C virus (HCV) depends on the GBF1-Arf1-COP-I pathway.
|
24058576 |
2013 |
|
Hernia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Joint laxity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
CTD_human |
These findings underline the importance of ARF1 in promoting metastasis and suggest that LM11 that inhibits ARF1 activation may represent a potential therapeutic approach to prevent or treat breast cancer metastasis.
|
27517156 |
2016 |
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
These findings underline the importance of ARF1 in promoting metastasis and suggest that LM11 that inhibits ARF1 activation may represent a potential therapeutic approach to prevent or treat breast cancer metastasis.
|
27517156 |
2016 |
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
In conclusion, this study provides a new mechanism by which ARF1 regulates cell migration and identifies this GTPase as a promising pharmacological target to reduce metastasis formation in breast cancer patients.
|
23707487 |
2013 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Activation of small GTPases such as Ras and Arf1 is a critical component of the signaling pathways for most of the receptors shown to be upregulated in advanced prostate cancer.
|
28830537 |
2017 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings collectively support the utility of ARF1 as a novel prognostic marker for gastric cancer and its role in cell invasion.
|
22348287 |
2012 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The CDKN2A tumor-suppressor locus on chromosome band 9p21, which encodes p16(INK4A), a negative regulator of cyclin-dependent kinases, and p14(ARF1), an activator of TP53, is inactivated in many human cancers by point mutation, promoter hypermethylation, and, often, deletion.
|
15495191 |
2005 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The CDKN2A tumor-suppressor gene in chromosome band 9p21 encoding CDKN2A (also known as p16, INK4A), a negative regulator of cyclin-dependent kinases, and p14(ARF1), an activator of TP53, is inactivated in many human cancers by point mutations, promoter hypermethylation, or deletions.
|
12696062 |
2003 |
|
Malignant tumor of cervix
|
0.010 |
Biomarker
|
disease |
BEFREE |
LncRNA TP73-AS1 is a novel regulator in cervical cancer via miR-329-3p/ARF1 axis.
|
31232491 |
2020 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.
|
27517156 |
2016 |
|
Mammary Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.
|
27517156 |
2016 |
|
Mammary Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells.
|
18990689 |
2008 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.
|
27517156 |
2016 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our data shed new light on the molecular mechanism of CAM-DR in MM, and targeting ARF1 may be a novel therapeutic approach for improving the effectiveness of chemotherapy in MM.
|
28238095 |
2017 |
|
Muscle Spasticity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neoplasm Invasiveness
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.
|
27517156 |
2016 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These findings underline the importance of ARF1 in promoting metastasis and suggest that LM11 that inhibits ARF1 activation may represent a potential therapeutic approach to prevent or treat breast cancer metastasis.
|
27517156 |
2016 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, this study provides a new mechanism by which ARF1 regulates cell migration and identifies this GTPase as a promising pharmacological target to reduce metastasis formation in breast cancer patients.
|
23707487 |
2013 |
|
Neoplasms
|
0.020 |
PosttranslationalModification
|
group |
BEFREE |
The results reported here provide a basis for a new hypotheses connecting EGFR gene amplification in GB cells with ARF1 gene promoter methylation, vesicle trafficking, membrane turnover and tumor metabolism.
|
28631186 |
2017 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Here, we show that Arf1 is the predominant Arf protein family member expressed in the neuroendocrine pancreatic tumour cell lines BON and QGP-1.
|
25754106 |
2015 |
|
Neuroendocrine Tumors
|
0.010 |
AlteredExpression
|
group |
BEFREE |
IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells.
|
25754106 |
2015 |
|
Osteopetrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, the present study established a new system approach for the investigation of microRNAs, and the microRNA-target pairs, particular has-miR-320a and Arf1, may have important roles in osteopetrosis.
|
24084574 |
2014 |